股票代码：002462 股票简称：嘉事堂 公告编号：2025-35 嘉事堂药业股份有限公司 关于召开 2025 年第三次临时股东会的通知公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、会议召开的基本情况 1、 股东会届次：本次股东会是嘉事堂药业股份有限公司 2025 年第三次临 时股东会。 2、 股东会召集人：公司董事会。 根据嘉事堂药业股份有限公司（以下简称"公司"）《章程》的相关规定，公 司第七届董事会第十八次会议于 2025 年 8 月 29 日召开，会议决议拟定于 2025 年 9 月 17 日（星期三）召开公司 2025 年第三次临时股东会。 3、 会议召开的合法、合规性说明：董事会召集本次股东会符合《公司法》、 《上市公司股东会规则》等有关法律、行政法规、部门规章、规范性文件和本公 司章程的规定。 4、 会议召开时间： （1） 现场会议召开时间：2025 年 9 月 17 日（星期三）15:00 （4） 根据相关法规应当出席股东会的其他人员。 8、现场会议地点：北京市海淀区昆明湖南路 11 号 1 号楼二层会议室 二、会议审议事项 （2） ...

证券代码：002462 证券简称：嘉事堂 公告编号：2025-30 嘉事堂药业股份有限公司 第七届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 嘉事堂药业股份有限公司（以下简称"公司""本公司"）第七届董事会第十 八次会议于 2025 年 8 月 18 日以电子邮件的方式发出会议通知。会议于 2025 年 8 月 29 日以现场结合通讯表决的方式召开。会议应表决的董事 9 名，实际表决 的董事 9 名。本次会议的召开及表决程序符合《公司法》《公司章程》及《董事 会议事规则》的有关规定。 二、董事会会议审议情况 1、关于 2025 年半年度报告及摘要的议案 本议案经第七届董事会审计委员会 2025 年第二次会议审议通过后提交董事 会审议。 表决结果：同意 9 票，反对 0 票，弃权 0 票，议案获得通过。 详 情 请 见 公 司 同 日 在 《 证 券 日 报 》、《 证 券 时 报 》 与 巨 潮 资 讯 网 （http://www.cninfo.com.cn）披露的《嘉事堂药业股份有限公司 2025 年半 ...

Group 1 - The company, Jia Shi Tang, reported a revenue of 9.699 billion yuan for the first half of 2025, representing a year-on-year decrease of 24.45% [1] - The net profit attributable to shareholders of the listed company was 107 million yuan, down 36.24% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 96.2624 million yuan, a year-on-year decline of 9.84% [1] - The basic earnings per share were 0.37 yuan [1]

嘉事堂8月29日披露半年报，公司上半年实现营业收入96.99亿元，同比下降24.45%；归属于上市公司股 东的净利润1.07亿元，同比下降36.24%；基本每股收益0.37元。 ...

嘉事堂药业股份有限公司 2025 年半年度报告全文 嘉事堂药业股份有限公司 2025 年半年度报告 2025-32 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 【2025 年 8 月】 1 嘉事堂药业股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 报告中对公司未来计划的前瞻性陈述不构成公司对投资者的实际承诺， 投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、预 测与承诺之间的差异。可能存在行业竞争、经营与管理、市场、国家政策等 风险，敬请广大投资者注意投资风险。 公司负责人徐曦、主管会计工作负责人黄奕斌及会计机构负责人(会计主 管人员)林军声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 以上文件均存放于公司投资证券部/董事会办公室 4 | 目录 | | --- | | 第一节 重要提示、目录和释义 2 | | --- | | 第二节 公司简介和主要财务指标 6 ...

Group 1 - The company focuses on wholesale distribution of pharmaceuticals and medical devices, professional logistics for medical products, and retail pharmacy as its main business areas [1] - The company aims to provide high-quality healthcare products and services to medical institutions, downstream distributors, and end consumers [1] - The current business also includes the sales of innovative drugs [1]

Core Insights - The pharmaceutical commercial sector experienced a slight increase of 0.33% on August 5, with Jia Shitang leading the gains [1] - The Shanghai Composite Index closed at 3617.6, up 0.96%, while the Shenzhen Component Index closed at 11106.96, up 0.59% [1] Stock Performance Summary - Top gainers included: - Jia Shitang (002462) with a closing price of 15.43, up 5.98% and a trading volume of 207,500 shares, totaling 315 million yuan [1] - Dajia Weikang (301126) at 66.00, up 5.82% with a volume of 349,800 shares, totaling 471 million yuan [1] - Baiyang Pharmaceutical (301015) at 23.11, up 3.22% with a volume of 132,200 shares, totaling 303 million yuan [1] - Other notable performers included: - Renmin Tongtai (600829) at 8.41, up 1.57% [1] - Jiyu Pingmin (301017) at 13.54, up 1.42% [1] Fund Flow Analysis - The pharmaceutical commercial sector saw a net outflow of 170 million yuan from institutional investors, while retail investors contributed a net inflow of 219 million yuan [2] - Notable fund flows included: - Jia Shitang (002462) with a net inflow of 43.79 million yuan from institutional investors, but a net outflow of 37.47 million yuan from retail investors [3] - Dajia Weikang (301126) had a net inflow of 12.46 million yuan from institutional investors, with retail investors showing a net outflow of 10.70 million yuan [3] - Renmin Tongtai (600829) recorded a net inflow of 7.73 million yuan from institutional investors [3]

会议明确，此次双认证的取得，是嘉事堂发展历程中具有里程碑意义的大事，更是深入贯彻中央八项规 定精神学习教育，落实全面从严治党要求的具体实践。合规贯标认证取得的背后，是切实扛起政治责 任，确保企业发展始终沿着正确政治方向前进的坚定决心；是强化行业自律，筑牢合规经营的"防火 墙"重要举措。彰显了嘉事堂对合规体系建设的坚定信念和对违规行为的"零容忍"。 （文章来源：华夏时报） 姚琴首先向嘉事堂表示祝贺。她表示，中质协质量保证中心是国内第一批成立的中字头认证机构，从 1993年到现在，做了30多年的管理体系认证。嘉事堂此次顺利获得合规管理体系认证证书，不仅凸显了 嘉事堂在合规管理和内控方面的卓越能力，更体现了嘉事堂作为央企的责任担当和不断自我改革的坚定 决心。 会议指出，合规是企业行稳致远的基石，更是创造价值的源动力。通过双认证，嘉事堂向市场、客户及 合作伙伴传递了嘉事堂坚守合规底线、追求卓越管理的决心。嘉事堂将以此次认证为全新起点，秉 持"人人讲合规，事事讲合规，时时讲合规，合规创造价值"的核心理念，不断深化合规管理体系建设， 重点推动合规管理与经营管理的深度融合，以专业化、精细化、系统化的合规能力，为业务拓展、风 ...

Market Overview - The pharmaceutical commercial sector increased by 1.04% on July 30, with Huaren Health leading the gains [1] - The Shanghai Composite Index closed at 3615.72, up 0.17%, while the Shenzhen Component Index closed at 11203.03, down 0.77% [1] Top Performers - Huaren Health (301408) closed at 15.01, up 5.48% with a trading volume of 334,100 shares and a transaction value of 499 million [1] - Jiazhang Tang (002462) closed at 14.67, up 4.19% with a trading volume of 232,300 shares and a transaction value of 346 million [1] - Laobaixing (603883) closed at 19.69, up 2.93% with a trading volume of 398,800 shares and a transaction value of 779 million [1] - China National Pharmaceutical (600056) closed at 11.28, up 2.64% with a trading volume of 656,900 shares and a transaction value of 747 million [1] Underperformers - Renmin Tongtai (600829) closed at 8.77, down 7.20% with a trading volume of 724,400 shares and a transaction value of 651 million [2] - Saily Medical (603716) closed at 30.89, down 2.31% with a trading volume of 444,300 shares and a transaction value of 1.385 billion [2] - Runda Medical (603108) closed at 18.20, down 1.83% with a trading volume of 299,700 shares and a transaction value of 552 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 62.07 million from institutional investors, while retail investors saw a net inflow of 64.93 million [2] - Major stocks like Laobaixing and China National Pharmaceutical had significant net inflows from retail investors, despite overall sector outflows [3] Individual Stock Analysis - Laobaixing (603883) had a net inflow of 62.57 million from institutional investors, but a net outflow of 45.34 million from retail investors [3] - China National Pharmaceutical (600056) saw a net inflow of 49.86 million from institutional investors, with a net outflow of 43.44 million from retail investors [3] - Huaren Health (301408) had a net inflow of 21.02 million from institutional investors, but a net outflow of 26.49 million from retail investors [3]

Group 1 - Changhua Group received a product purchase contract for carbon-ceramic brake discs, with a total sales amount expected to exceed 100 million yuan over a 5-year lifecycle, starting mass production in Q2 2026 [1] - Zhongke Environmental reported a net profit of 196 million yuan for the first half of 2025, a year-on-year increase of 19.83%, with revenue of 848 million yuan, up 4.48% [1] - WuXi AppTec's net profit for the first half of 2025 grew by 101.92% to 8.561 billion yuan, with revenue of 20.799 billion yuan, a 20.64% increase [1][2] - Sujiao Technology's net profit decreased by 39.54% to 95.39 million yuan, with revenue down 13.75% to 1.776 billion yuan [1] - Jucheng Co. reported a net profit of 205 million yuan, a significant increase of 43.5%, with revenue of 575 million yuan, up 11.69% [1] Group 2 - Sanxiang New Materials plans to invest up to 300 million yuan in a zirconium-hafnium separation project, with a production capacity of 20,000 tons [1] - Koweil received government subsidies totaling 4.9752 million yuan, accounting for 10.14% of its audited net profit [1] - Xinhua Medical obtained two Class II medical device registration certificates for digital X-ray machines [1] - Huanxu Electronics reported a net profit of 638 million yuan, down 18.66%, with total revenue of 27.214 billion yuan, a slight decrease of 0.63% [1] - Zhenhua Co.'s general manager was fined 100,000 yuan for violations related to stock trading by his child [1] Group 3 - Huafeng Aluminum signed a raw material purchase contract worth over 7.2 billion yuan for a five-year period, committing to purchase at least 360,000 tons of raw materials [1] - Hongxin Technology received a project designation letter and procurement contract from a major domestic automotive brand [1] - Meihe Co. obtained a patent for a device used in supporting automatic flipping on conveyor lines in the automotive manufacturing sector [1] - Xin Hongye's subsidiary won a bid for an electrical penetration project worth 40.8831 million yuan [1] - Fuan Pharmaceutical's subsidiary received a drug registration certificate for an injection used in liver disease treatment [1] Group 4 - Tianzhong Precision's subsidiary's bankruptcy liquidation application was accepted by the court due to insufficient assets to cover debts [1] - Zhonghong Medical's subsidiary received medical device registration for infusion pumps and information collection systems [1] - Keda Li's subsidiary completed a capital increase, raising its registered capital from 200 million yuan to 400 million yuan [1] - Xingye Technology applied for a credit limit of 372 million yuan from Guangfa Bank [1] - Hengrui Medicine signed a collaboration agreement with GSK, involving a potential total payment of approximately 12 billion USD based on project milestones [1]